Revosimeline
![]() | |
| Clinical data | |
|---|---|
| Drug class | Muscarinic acetylcholine receptor agonist |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C18H29N3O3 |
| Molar mass | 335.448 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Revosimeline is a muscarinic acetylcholine receptor agonist which has not been marketed at this time.[1][2][3] It is said to be an agonist of the muscarinic acetylcholine M1 receptor.[3] The drug appears to be structurally distinct from earlier muscarinic acetylcholine receptor agonists like milameline and xanomeline.[4] Its INN was designated in 2018.[5]
References
- ↑ World Health Organization (2024). "Use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances, 2024" (PDF). World Health Organization. p. 102. Retrieved 21 October 2024.
-meline cholinergic agents (muscarine receptor agonists/partial antagonists used in the treatment of Alzheimer's disease) E.1.0.0 (USAN: cholinergic agonists (arecoline derivatives used in the treatment of Alzheimer's disease)) [...] alvameline (79), cevimeline (76), itameline (77), milameline (74), revosimeline (120), sabcomeline (76), tazomeline (77), xanomeline (70)
- ↑ "Proposed INN: List 120: Revosimelinum" (PDF). WHO Drug Information. 32 (4): 674. 2018.
p. 382 revosimelinum revosimeline [...] replace the mode of action by the following one [...] muscarinic receptor agonist [...]
- 1 2 "REVOSIMELINE". Inxight Drugs. National Center for Advancing Translational Sciences (NCATS). Retrieved 26 October 2024.
- ↑ "Revosimeline". PubChem. U.S. National Library of Medicine. Retrieved 26 October 2024.
- ↑ "Recommended INN: List 80: revosimelinum" (PDF). WHO Drug Information. 32 (3): 482. 2018.
